2 days Ago By ABMN Staff
Envestnet Asset Management Inc. cut its position in Exact Sciences Co. ( NASDAQ:EXAS – Free Report ) by 14.
8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 255,244 shares of the medical research company’s stock after selling 44,424 shares during the period. Envestnet Asset Management Inc.
’s holdings in Exact Sciences were worth $14,342,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Asset Planning Inc bought a new position in Exact Sciences in the fourth quarter worth approximately $40,000.
Modus Advisors LLC acquired a new stake in Exact Sciences in the 4th quarter valued at $43,000. AlphaQuest LLC increased its stake in Exact Sciences by 22,825.0% during the 4th quarter.
AlphaQuest LLC now owns 917 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 913 shares in the last quarter. SBI Securities Co. Ltd.
bought a new stake in Exact Sciences during the 4th quarter valued at $66,000. Finally, Kieckhefer Group LLC bought a new position in shares of Exact Sciences in the fourth quarter valued at $188,000. 88.
82% of the stock is owned by institutional investors. Exact Sciences Price Performance Shares of NASDAQ EXAS opened at $42.26 on Thursday.
The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.
97. The stock has a fifty day simple moving average of $46.28 and a two-hundred day simple moving average of $55.
39. Exact Sciences Co. has a 1-year low of $39.
97 and a 1-year high of $72.83. The firm has a market cap of $7.
85 billion, a price-to-earnings ratio of -7.59 and a beta of 1.14.
Analysts Set New Price Targets EXAS has been the subject of several recent research reports. Guggenheim reissued a “buy” rating and set a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th.
Piper Sandler lowered their price objective on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th.
Bank of America cut their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th.
William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Finally, Benchmark reaffirmed a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th.
Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $69.
25. Check Out Our Latest Report on Exact Sciences Exact Sciences Company Profile ( Free Report ) Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. See Also Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co.
( NASDAQ:EXAS – Free Report ). Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
_0.jpg?itok=yAIF6nFK)
